Shots:

• Under the collaboration, SEED will handle preclinical studies of the targets incl. E3 ligase selection & identification while Eisai secures exclusive development & commercialization rights of the resulting compounds
• SEED will obtain a total of ~1.5B upfront, preclinical, clinical, regulatory & sales milestones along with tiered royalties if Eisai exercises its rights
• In addition, SEED has secured $24M in series A-3 financing which will be used to advance its oral RBM39 degrader into P-I for cancer & its Tau degrader into in vivo efficacy for Alzheimer's in 2025 with IND in 2026 plus will scale its TPD platform development. A second close will be in Q4’24